{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0029","statisticalComment":"Reported p-values are unadjusted and 1-sided","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48","upperLimit":"61","value":"54"},{"groupId":"OG001","lowerLimit":"35","upperLimit":"48","value":"41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"212"}],"units":"Participants"}],"description":"Comparing regimens that contain carboplatin (arms 3\\&4) versus not (arms 1\\&2).","dispersionType":"95% Confidence Interval","groups":[{"description":"Factor A is the addition or not of carboplatin: the experimental regimens included carboplatin (Arms 3 \\& 4).","id":"OG000","title":"Factor A: Carboplatin"},{"description":"Factor A is the addition or not of carboplatin; the control regimens did not include carboplatin (Arms 1 \\& 2).","id":"OG001","title":"Factor A: No Carboplatin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At the time of definitive surgical removal, up to 28 weeks","title":"Pathologic Complete Response (pCR) in the Breast and Axilla. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is) Plus the Absence of Any Tumor Deposit >0.2 mm in Sampled Axillary Nodes (ypT0/isN0).","type":"SECONDARY","unitOfMeasure":"percentage of participants with pCR"}